Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular characterization of acute lymphoblastic leukemia with CRLF2 overexpression in childhood

ABSTRACT: Molecular characterization of acute lymphoblastic leukemia with CRLF2 overexpression in childhood

PROVIDER: PRJEB14218 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1433115.fastq.gz	Fastqsanger.gz
	ERR1433116.fastq.gz	Fastqsanger.gz
	ERR1433117.fastq.gz	Fastqsanger.gz
	ERR1433118.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Molecular characterization of acute lymphoblastic leukemia with CRLF2 overexpression in childhood

Project description:To investigate the different susceptibility to relapse, CRLF2-overexpressing cases with and without P2RY8-CRLF2 fusion were analyzed by next-generation sequencing based gene expression profiling.

2016-08-30 | E-MTAB-4737 | biostudies-arrayexpress

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2019-02-25 | PXD010175 | Pride

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2020-01-29 | MSV000084862 | MassIVE

Transcriptome analysis of childhood acute lymphoblastic leukemia cell lines

Project description:Transcriptome profiling of 49 childhood acute lymphoblastic leukemia cell lines and 2 EBV transformed B-cell lines.

2022-02-16 | GSE168386 | GEO

Proteomics analysis of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilities

Project description:Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and it has a 5-year survival rate of 85% for European children. But for subsets of patients who fail to respond to standard of care chemotherapeutics, treatment options are limited, and clinical prognosis is poor. To establish a platform and methodology to better characterize ALL subtypes and identify their pharmacologic vulnerabilities, we assembled a biobank of 49 readily available childhood ALL cell lines representing diverse immunotypes and genetic profiles. Using these cell lines, we performed comprehensive multi-omic analyses, providing proteomic, transcriptomic and pharmacoproteomic characterization of childhood ALL. We used this resource to characterize the functional impact of genetic fusions and cellular differentiation states on the proteome. Additionally, we identified a novel drug vulnerability in one of the ALL subtypes. Our results are provided as an interactive online data portal with navigable proteomics, transcriptomics, and drug sensitivity profiles.

2022-03-26 | PXD023662 | Pride

circRNA expression in relapsed childhood acute lymphoblastic leukemia

Project description:3 patients with childhood acute lymphoblastic leukemia were diagnosed with relapsed, and the matched new diagnosed blood samples were enrolled as controls. CirRNA array were conducted for detecting the expression of miRNA in above samples.

2025-03-01 | E-MTAB-13177 | biostudies-arrayexpress

miRNA expression in relapsed childhood acute lymphoblastic leukemia

Project description:3 patients with childhood acute lymphoblastic leukemia were diagnosed with relapsed, and the matched new diagnosed blood samples were enrolled as controls. MiRNA array were conducted for detecting the expression of miRNA in above samples.

2025-03-01 | E-MTAB-13176 | biostudies-arrayexpress

Genomic profiling in Down syndrome pediatric acute lymphoblastic leukemia

Project description:Patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) have distinct clinical and biological features. Whereas most DS-ALL cases lack the sentinel cytogenetic lesions that guide risk assignment in childhood ALL, JAK2 mutations and CRLF2 overexpression are highly enriched. To further characterize the unique biology of DS-ALL, we performed genome-wide profiling of 58 DS-ALL and 35 non-Down syndrome (NDS) ALL cases by DNA copy number, loss of heterozygosity, gene expression, and methylation analyses. We report novel deletions within the 6p22 histone gene cluster as significantly more frequent in DS-ALL, occurring in 12 DS (24%) and only a single NDS case (3%) (Fisher’s exact p = 0.013). Homozygous deletions yielded significantly lower histone expression levels, and were associated with higher methylation levels, distinct spatial localization of methylated promoters, and enrichment of highly methylated genes for specific pathways and transcription factor binding motifs. Gene expression profiling identified CRLF2 overexpression in nearly half DS-ALL cases, and supervised analysis identified an associated 39-gene signature. However, no expression signature was identified for DS-ALL overall, nor for histone status, suggesting that DS-ALL constitutes several, heterogeneous molecular entities. Characterization of pathways associated with histone deletions and high CRLF2 expression may identify opportunities for novel targeted interventions. This SuperSeries is composed of the SubSeries listed below.

2011-07-12 | GSE21094 | GEO

Genomic characterization implicates iAMP21 as a primary genetic event in childhood B-cell precursor acute lymphoblastic leukaemia

Project description:Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct subgroup of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) shown to have a dismal outcome on standard therapy. For improved diagnosis and prognosis of these patients, the initiating genetic events need to be elucidated. To investigate the genetic basis, the genomes of 94 iAMP21 patients were interrogated by genomic arrays, FISH and MLPA. Detailed mapping of chromosome 21 refined the common region of amplification (CRA) to 5.1 Mb; including the RUNX1 gene, miR-802 and genes mapping to the Down Syndrome Critical Region. Over a quarter of copy number alterations targeted chromosome 21, including telomeric deletions in 88% of patients. Global analysis by genomic arrays identified recurrent abnormalities affecting genes in key pathways. The frequency of these abnormalities were determined by FISH and/or MLPA; IKZF1 (22%), CDKN2A/B (17%), PAX5 (8%), ETV6 (19%) and RB1 (37%). Study of the clonal architecture provided evidence that these abnormalities, and P2RY8-CRLF2, were secondary to chromosome 21 instability. This study provides convincing evidence that chromosome 21 instability is the only abnormality common to all iAMP21 patients and the initiating event is likely hidden within the complex structural rearrangements of this abnormal chromosome. DNA copy number analysis of 17 diagnostic and 1 relapse acute lymphoblastic leukaemia samples was performed using agilent 185K microarrays. These samples were hybridised against gender matched reference DNA.

2012-03-02 | E-GEOD-26192 | biostudies-arrayexpress